Waldencast plc - Class A Ordinary Share (WALD)

Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices

Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue

Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million.

First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025

A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair*

U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market

Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand’s Addressable Market in the U.S.

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio

Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio

Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA

A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion

Q4 Net Revenue of $72.1 million, 29.4% Comparable Net Revenue Growth and $11.2 million of Adjusted EBITDA, doubling from Q4 2023

LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its Fourth Quarter and Fiscal Year 2024 conference call and webcast. As previously announced, the Company will issue its Fourth Quarter and Fiscal Year 2024 results on March 18, 2025 after the close of the U.S. market.

LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced its participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit being held on February 26, 2025 in New York, New York.

New Skincare Solutions to Target Skin Brightening, Oxidative Stress, and Hydration for a Healthier, More Radiant Complexion

LONDON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, announced upcoming earnings release, conference call and webcast information for the fourth quarter and full fiscal year 2024 and first, second, and third quarters of fiscal year 2025. The webcasts will be available on the Investor Relations page on the company's website at https://ir.waldencast.com/ approximately 2 weeks prior to the events.

LONDON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced its participation in the 2025 International Master Course on Aging Science (IMCAS) World Congress, which will be held in Paris from January 30, 2025 to February 1, 2025.

WHITE PLAINS, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the Company will participate in investor meetings and host a presentation at the ICR Conference 2025 being held at The Grande Lakes Orlando in Orlando, Florida on January 13, 2025.

$70.2 million of Net Revenue Q3 2024+34.6% Comparable Net Revenue GrowthBoth brands accelerating from Q2 2024+45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023

LONDON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its Third Quarter Fiscal 2024 conference call and webcast. As previously announced, the Company will issue its Third Quarter Fiscal 2024 results on November 20, 2024 after the close of the U.S. market.